| The trials and errors in MS therapy. | |
| | |
MedLine Citation:
|
PMID: 18808741 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
The development programme for novel therapies in multiple sclerosis (MS) has an impressive track record which is unique in the field of neurology, and has led to the approval of several drugs during the past decade. However, therapeutic prosperities face numerous trials that either failed to show efficacy or that had to be halted because of other reasons including adverse events. Moreover, certain treatment strategies are controversial, both for reasons of practicability and for their true clinical benefit. There are serious caveats that highly immunoselective approaches such as monoclonal antibodies can only be applied at the expense of an increased risk of acute or long-term adverse effects. This review focuses on the most important clinical trials on yet unlicensed compounds in relapsing-remitting and secondary-progressive MS which failed, were halted or are associated with significant adverse effects since 2002. Furthermore, we discuss the implications these experiences have for our current view of MS pathogenesis as well as future study design. Examples include agents that target leukocyte differentiation molecules, co-stimulatory molecules, adhesion molecules and chemotaxis, as well as novel immunomodulators and anti-infective therapies. |
| | |
Authors:
|
Christoph Kleinschnitz; Sven G Meuth; Heinz Wiendl |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't; Review |
Journal Detail:
|
Title: International MS journal / MS Forum Volume: 15 ISSN: 1352-8963 ISO Abbreviation: Int MS J Publication Date: 2008 Sep |
Date Detail:
|
Created Date: 2008-09-23 Completed Date: 2008-11-18 Revised Date: 2008-12-03 |
Medline Journal Info:
|
Nlm Unique ID: 9804403 Medline TA: Int MS J Country: England |
Other Details:
|
Languages: eng Pagination: 79-90 Citation Subset: IM |
Affiliation:
|
Department of Neurology, University of Wurzburg, Wurzburg, Germany. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Antibodies, Monoclonal
/
adverse effects,
therapeutic use Clinical Trials as Topic Drugs, Investigational / adverse effects, therapeutic use* Humans Multiple Sclerosis, Chronic Progressive / drug therapy* Multiple Sclerosis, Relapsing-Remitting / drug therapy* Treatment Failure |
| Chemical | |
Reg. No./Substance:
|
0/Antibodies, Monoclonal; 0/Drugs, Investigational |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Determination of angiogenic factors in serum by protein array in patients with renal cell carcinoma.
Next Document: Wilhelm Uhthoff: a phenomenon 1853 to 1927.